ArticleGut2007
High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
Article in Gut, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 114 citations in OpenAlex.
- G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence.World journal of gastroenterology · 2009Trial
- Autoimmunity and peginterferon therapy for polycythemia vera.HemaSphere · 2026Review
- Manganese Exacerbates ConA-Induced Liver Inflammation via the cGAS-STING Signaling Pathway.Inflammation · 2024Article
- Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy.World journal of hepatology · 2022Article
- Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms.International journal of molecular sciences · 2021Review
- GPX4-Regulated Ferroptosis Mediates S100-Induced Experimental Autoimmune Hepatitis Associated with the Nrf2/HO-1 Signaling Pathway.Oxidative medicine and cellular longevity · 2021Article
- Autoimmune Hepatitis in the Liver Transplant Graft.Clinics in liver disease · 2017Review
- De novo autoimmune hepatitis in liver transplant: State-of-the-art review.World journal of gastroenterology · 2016Review
- Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research.Transplantation · 2016Review
- Liver transplantation and autoimmune hepatitis.Intractable & rare diseases research · 2015Review
- Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.Hepatology international · 2014Article
- Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.World journal of gastroenterology · 2014Review
- Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival.Hepatology international · 2013Article
- The prediction of immunological dysfunction during antiviral therapy for HCV after liver transplantation: can we improve outcomes?Hepatology international · 2013Article
- Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.World journal of gastroenterology · 2013Article
- Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy.World journal of gastroenterology · 2013Article
- Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation.PloS one · 2013Article
- De novo autoimmune hepatitis associated with PTH(1-34) and PTH(1-84) administration for severe osteoporosis in a liver transplant patient.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012Article
- Liver transplantation and hepatitis C.International journal of hepatology · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterferon may trigger autoimmune disorders, including autoimmune hepatitis, in immunocompetent patients. To date, no such disorders have been described in liver transplanted patients.
methods9 of 44 liver transplanted patients who had been receiving pegylated-interferon alpha-2b and ribavirin for at least 6 months for hepatitis C virus (HCV) recurrence, developed graft dysfunction despite on-treatment HCV-RNA clearance in all but one case. Laboratory, microbiological, imaging and histological evaluations were performed to identify the origin of graft dysfunction. The International Autoimmune Hepatitis scoring system was also applied.
resultsIn all cases infections, anastomoses complications and rejection were excluded, whereas the autoimmune hepatitis score suggested a "probable autoimmune hepatitis" (score from 10 to 14). Three patients developed other definite autoimmune disorders (overlap anti-mitochondrial antibodies (AMA)-positive cholangitis, autoimmune thyroiditis and systemic lupus erythematosus, respectively). In all cases, pre-existing autoimmune hepatitis was excluded. Anti-lymphocyte antibodies in immunosuppressive induction treatment correlated with the development of the disorder, whereas the use of granulocyte colony-stimulating factor to treat interferon-induced neutropenia showed a protective role. Withdrawal of antiviral treatment and treatment with prednisone resulted in different outcomes (five remissions and four graft failures with two deaths).
conclusionsDe novo autoimmune hepatitis should be considered in differential diagnosis along with rejection in liver transplanted patients developing graft dysfunction while on treatment with interferon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.